Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Farmers Insurance
Cipla
McKesson
Teva
Colorcon
Chinese Patent Office
Dow

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,562,375

« Back to Dashboard

Which drugs does patent 6,562,375 protect, and when does it expire?

Patent 6,562,375 protects MYRBETRIQ and is included in one NDA.

This patent has twenty patent family members in sixteen countries.
Summary for Patent: 6,562,375
Title: Stable pharmaceutical composition for oral use
Abstract:The present invention is to provide a stable pharmaceutical composition for oral use and preparation thereof in which changes are prevented in drug release at stored even under the exposure to light by adding yellow ferric oxide and/or red ferric oxide in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The present invention is to further provide a method for preventing changes in drug release at stored under the exposure to light in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The quality assurance period of the product can be prolonged and the product value can be improved by the present invention.
Inventor(s): Sako; Kazuhiro (Shizuoka, JP), Sawada; Toyohiro (Shizuoka, JP), Yoshihara; Keiichi (Shizuoka, JP), Yoshioka; Tatsunobu (Shizuoka, JP), Watanabe; Shunsuke (Shizuoka, JP)
Assignee: Yamanouchi Pharmaceuticals, Co., Ltd. (Tokyo, JP)
Application Number:09/629,405
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,562,375
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 6,562,375

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-001 Jun 28, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Apgdi MYRBETRIQ mirabegron TABLET, EXTENDED RELEASE;ORAL 202611-002 Jun 28, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Citi
UBS
Healthtrust
QuintilesIMS
Queensland Health
Medtronic
Cerilliant
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.